Long-term lebrikizumab study for moderate to severe eczema
Treatments studied
Part of Genetic & congenital, Immune system & allergy, Skin clinical trials.
This Phase 3 trial studies whether lebrikizumab is safe and continues to work over the long term for children and teens with moderate-to-severe atopic dermatitis (eczema). It’s meant for people who already finished a related earlier study and can safely continue.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have participated in the earlier study (KGBI) and fully completed its treatments and last visit.
- If you take part as someone who could become pregnant, you must use highly effective birth control during the study (following local study rules).
- You must not have had a serious side effect during KGBI that doctors felt was related to lebrikizumab and made continuing too risky.
- You must not have had a side effect during KGBI that doctors felt was related to lebrikizumab and caused stopping the study treatment.
- You must not be pregnant, breastfeeding, or planning pregnancy or breastfeeding during the trial.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a daily pill called Abrocitinib to see if it can help children ages 6 to 11 with moderate-to-severe eczema that hasn't gotten better with creams or ointments. Eczema (also called atopic dermatitis) causes itchy, red skin, and this medicine might calm the immune response to reduce itching and rashes.
This study tests the long-term safety and effectiveness of abrocitinib (Cibinqo) for children aged 6 to 12 with moderate to severe eczema that hasn't improved with creams. It may help their skin clear and reduce itching.
This study tests an experimental treatment for people with moderate to severe eczema that has lasted at least a year. It aims to see if the new medicine can help control symptoms better than current options.
This study looks at how well nemolizumab works in everyday practice for people with moderate-to-severe atopic dermatitis (eczema). It helps researchers understand the real-world benefits and safety of this treatment.
This study looks at how lebrikizumab (Ebglyss) affects daily life and skin symptoms in adults with moderate-to-severe eczema. You may join if your doctor has prescribed this medication as part of your regular care.
This study tests how well lebrikizumab (Ebglyss), an approved treatment for moderate-to-severe atopic dermatitis (eczema), works in everyday clinical practice. It aims to see how the drug affects your symptoms and quality of life over time, helping guide better treatment decisions.
Hear when a new Atopic Dermatitis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.